Cost-effectiveness analysis of ceftazidime-levofloxacin and cefotaxime-erythromycin as empirical antibiotic combinations in respiratory infection-induced sepsis by Destiani, Dika P. et al.
  
 University of Groningen
Cost-effectiveness analysis of ceftazidime-levofloxacin and cefotaxime-erythromycin as
empirical antibiotic combinations in respiratory infection-induced sepsis
Destiani, Dika P.; Milanda, Tiana; Susilawati, Susilawati; Suwantika, Auliya A.; Pradipta, Ivan
S.; Halimah, Eli; Diantini, Ajeng; Sumiwi, Sri A.; Muhtadi, Ahmad; Subarnas, Anas
Published in:
Asian Journal of Pharmaceutical and Clinical Research
DOI:
10.22159/ajpcr.2017.v10s2.19515
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Destiani, D. P., Milanda, T., Susilawati, S., Suwantika, A. A., Pradipta, I. S., Halimah, E., ... Abdulah, R.
(2017). Cost-effectiveness analysis of ceftazidime-levofloxacin and cefotaxime-erythromycin as empirical
antibiotic combinations in respiratory infection-induced sepsis. Asian Journal of Pharmaceutical and Clinical
Research, 10(Special Issue may), 119-121. https://doi.org/10.22159/ajpcr.2017.v10s2.19515
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 11-12-2019
Special Issue (May)
Online - 2455-3891 
Print - 0974-2441
II-Indonesian Conference on Clinical Pharmacy
COST-EFFECTIVENESS ANALYSIS OF CEFTAZIDIME-LEVOFLOXACIN AND 
CEFOTAXIME-ERYTHROMYCIN AS EMPIRICAL ANTIBIOTIC COMBINATIONS IN RESPIRATORY 
INFECTION-INDUCED SEPSIS
DIKA P DESTIANI1*, TIANA MILANDA1, SUSILAWATI SUSILAWATI2, AULIYA A SUWANTIKA1,3, IVAN S PRADIPTA1, 
ELI HALIMAH1, AJENG DIANTINI1, SRI A SUMIWI1, AHMAD MUHTADI1, ANAS SUBARNAS1, KERI LESTARI1, 
RIZKY ABDULAH1
1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Indonesia. 2Department of Pharmacy, 
Hasan Sadikin Hospital, Bandung, Indonesia. 3Department of Pharmacy, University of Groningen, Groningen, Netherlands.  
Email: dika.pramita@unpad.ac.id
Received: 24 December 2016, Revised and Accepted: 24 January 2017
ABSTRACT
Objective: Pharmacoeconomics has become an important consideration in the selection of therapies, including in patients with sepsis caused by respiratory infection. The aim of this study was to determine the most cost-effective antibiotic combination for respiratory infection-induced sepsis at a public hospital in Bandung, Indonesia.
Methods: This retrospective observational study was conducted at one of the public hospitals in Bandung. Two interventions were analyzed: (I1) Ceftazidime-levofloxacin and (I2) cefotaxime-erythromycin; and compared to the major treatment (I0, the use of other antibiotic combinations). Data were collected from the medical records of inpatients with respiratory infection-induced sepsis from 2010 to 2012. Health-care perspective was applied by considering only direct medical costs, which were calculated from a variable (drug, administrative, and treatment cost) and fixed cost (hospitalization).
Results: Comparing with I0, net cost per life saved was calculated to be $3,350 (I1) and $1,589 (I2). Number of patients survived was considered to be the most significant parameter on affecting the calculation of net cost per life saved.
Conclusion: I2 was more cost effective than I1, compared to I0.
Keywords: Empirical therapy, Cost-effectiveness, Pharmacoeconomics, Sepsis, Antibiotics.
INTRODUCTIONSepsis is a systemic inflammatory response triggered by a known or highly suspected pathogen. The mortality rate of severe sepsis in the world remains high, at approximately 28% [1]. The previous studies confirmed that respiratory infection is the major cause of sepsis [2,3]. Sepsis caused by respiratory infection can be treated with a combination of a beta-lactamase or cephalosporin plus a fluoroquinolone or macrolide [4,5]. In Indonesia, the most commonly used antibiotic combinations related to sepsis therapy are ceftazidime-levofloxacin and cefotaxime-erythromycin [5]. Hence, in this study, we analyzed the cost-effectiveness of both antibiotic combinations in patients with respiratory infection-induced sepsis.
METHODSThis retrospective observational study was conducted at one of the public hospitals in Bandung since the prevalence of sepsis caused by respiratory infection was very high (49%) [4]. Two interventions were analyzed: (I1) Ceftazidime-levofloxacin and (I2) cefotaxime-erythromycin; and compared to the major treatment (I0, the use of other antibiotic combinations), which was most commonly used at this hospital and yet in contrast with the general situation in Indonesia. Data were collected from the medical records of inpatients with respiratory infection-induced sepsis from 2010 to 2012. Health-care perspective was applied by considering only direct medical costs, which were calculated from a variable (drug, administrative, and treatment costs) and fixed cost (hospitalization). This study was approved by the Ethical Committee of Universitas Padjadjaran, Indonesia.
A total of 408 sepsis patients (adult patients [18-59 years] with respiratory infection-induced sepsis in 2010-2012 and treated for at least 3 days with an empirical antibiotic combination) were included in this study, while patient transferred from other hospital or with incomplete medical records were excluded from the study.
COST-EFFECTIVENESS ANALYSIS CALCULATIONNet cost per life saved was calculated by considering the total direct medical cost per life saved from I1 to I2, compared with I0. Discounting the costs was unnecessary since all costs occurred within 1 year. The currency was converted from the Indonesian Rupiah to the US Dollar using the World Bank purchasing power parity conversion factor [6].
RESULTSDespite the total number of eligible patients in this study was 90 patients, there were only 24 patients survived (7, 5, and 12 patients for I1, 12, and I0, respectively). The average direct medical costs in this study were $3,786; $6,427; and $3,605 for I1, 12, and I0, respectively. In addition, the average direct medical costs in this study were $3,786; $6,427; and $3,605 for all interventions (Table 1).Comparing with I0, net cost per life saved was calculated to be $3,350 (I1) and $1,589 (I2). Number of patients survived was considered to be the most significant parameter on affecting the calculation of net cost per life saved (Table 2).
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DISCUSSIONAlthough the drug costs for I2 ($82.43) was lower than I1 ($448.66), the average direct medical cost for I2 ($6,426.94) was higher than I1 ($3,786.69). This cost difference was due to the extra cost caused by the adverse effects of cefotaxime-erythromycin. This combination causes thrombocytopenia, possibly requiring thrombocyte transfusion, which costs approximately $890.91/unit. One of the physiological changes in sepsis patients is a decreased thrombocyte level due to thrombocytopenia [7], and the cefotaxime-erythromycin combination may worsen this condition [8]. If the decreased thrombocyte level is <100,000/mm3, thrombocyte transfusion will be needed to avoid spontaneous bleeding [5,6]. In this study, six patients using cefotaxime-erythromycin were diagnosed with thrombocytopenia, of whom one was given a thrombocyte transfusion due to a thrombocyte level of <50,000/mm3 [9].Cost per life saved was calculated to be $3,350 and $1,589 for I1 and I2, compared to I0. This could be interpreted that the combination of 
Table 1: Direct medical costs (total patient=90; death=66; survived=24)
No. Length of stay I1=Ceftazidime‑levofloxacin
(Total patient‑32; Death‑25; Survived‑7)
Total direct 
medical cost ($)
Variable cost ($) Fixed cost ($)
Drug cost Administrative costa Treatment costsb Room1 13 278.77 256.88 1,535.18 1,486.19 3,557.022 7 242.74 403.88 520.88 801.97 1,969.473 17 644.77 114.33 1,423.07 1,942.33 4,124.514 16 644.77 54.94 1,432.83 1,828.30 3,960.845 6 241.79 19.30 1,233.19 687.93 2,182.216 4 161.19 31.18 765.72 459.86 1,417.957 18 926.58 285.09 6,026.80 2,056.37 9,294.84Total 3,140.61 1.165,60 12,937.67 9,262.95 26,506.83Average 12 448.66 166.52 1,848.24 1,323.28 3,786.69
No. Length of stay I2=Cefotaxime‑erythromycin
(Total patient‑16; Death‑11; Survived‑5)
Total direct 
medical cost ($) 
Variable cost ($) Fixed cost ($)
Drug cost Administrative costa Treatment costsb Room1 14 131.98 320.73 16,135.64 1,600.22 18,188.572 12 46.70 31.18 2,219.46 1,372.15 3,669.493 13 35.02 688.97 2,295.95 1,486.19 4,506.134 8 93.39 558.30 1,921.79 916.00 3,489.505 10 105.07 23.76 1,008.09 1,144.08 2,280.99Total 412.16 1,622.94 23,580.93 6,518.64 32,134.67Average 11 82.43 324.59 4,716.19 1,303.73 6,426.94
No. Length of stay I0=Major treatmentc
(Total patient‑42; Death‑30; Survived‑12)
Total direct 
medical cost ($)
Variable cost ($) Fixed cost ($)
Drug Administrative costa Treatment costsb Room1 30 1,192.04 7.42 1,921.18 3,424.81 6,545.462 11 167.80 700.85 2,884.79 1,258.11 5,011.563 19 652.41 120.49 395.06 2,170.41 3,338.374 15 371.41 218.27 514.21 1,714.26 2,818.165 5 1,206.39 237.58 1,108.50 573.90 3,126.366 13 504.47 301.42 791.36 1,486.19 3,083.447 7 288.46 19.30 486.28 801.97 1,596.018 9 268.25 23.76 438.74 1,030.04 1,760.799 28 20.37 503.36 2,394.14 3,196.74 6,114.6110 15 617.45 23.76 484.84 1,714.26 2,840.3111 14 626.76 35.64 773.83 1,600.22 3,036.4512 7 1,007.80 889.43 1,286.70 801.97 3,985.90Total 6,923.61 3,081.28 13,479.63 19,772.88 43,257.40Average 14 576.97 256.77 1,123.30 1,647.74 3,604.79aAdmininstrative cost - Preparation and administrative costs. bTreatment costs - Monitoring costs and costs of treatment, including adverse events and treatment failure. cMajor treatment - Others antibiotics treatment beside the two antibiotics which are compared in this research: Ampicillin-ciprofloxacin, cefotaxime-azithromycin, cefotaxime-metronidazole, ceftriaxone-metronidazole, ceftazidime-ciprofloxacin, ceftazidime-metronidazole. Intervention 0: I0, Intervention 1: I1, Intervention 2: I2
Table 2: Sensitivity analyses
Scenarios Net cost per life 
saved ($)
I1 I2Base-casea 3,350 1,589
Drug cost (25% ↑) 3,193 1,574
Drug cost (25% ↓) 3,507 1,604
Administrative cost (25% ↑) 3,292 1,531
Administrative cost (25% ↓) 3,408 1,647
Treatment cost (25% ↑) 2,703 747
Treatment cost (25% ↓) 3,997 2,431
Fixed cost (25% ↑) 2,887 1,356
Fixed cost (25% ↓) 3,813 1,822
Number of patients survived (25% ↑) 5,154 1,934
Number of patients survived (25% ↓) 2,482 1,348aNet cost per life saved = (Total cost I1-Total cost I0)/(number of survived patients I1-Number of survived patients I0). Intervention 0: I0, Intervention 1: I1, Intervention 2: I2
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cefotaxime-erythromycin was more cost effective than ceftazidime-levofloxacin. Thus, also considering the pattern of microbial resistance, the cefotaxime-erythromycin combination could be the better choice of empirical antibiotics in patients with sepsis caused by respiratory infections, as the combination may increase the number of lives saved. Regarding the sensitivity analyses, number of patients survived was the most significant parameter on affecting the calculation of net cost per life saved, compared to other parameters (e.g., variable and fixed costs).
LimitationsDespite the fact that this study is the first economic evaluation study on sepsis treatment in Indonesia, it obviously has several limitations. First, our study was an observational study, and we did not randomized patients into groups. Yet, according to a previous study [10], this approach also has an advantage since it can better reflect clinical practice. Second, we obtained medical costs from a public hospital in Indonesia which might be cheaper than others. Thus, if sepsis patients were treated in a private hospital, the cost-effective analysis might yield different results. Based on those limitations, further economic evaluation studies are still required in the future.
CONCLUSIONThe use of cefotaxime-erythromycin was more cost effective than ceftazidime-levofloxacin, compared to the use of major treatment.
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